US4197299A - Anti-hypertensive derivatives of ergoline-2-thioethers and their sulphoxides - Google Patents
Anti-hypertensive derivatives of ergoline-2-thioethers and their sulphoxides Download PDFInfo
- Publication number
- US4197299A US4197299A US05/917,335 US91733578A US4197299A US 4197299 A US4197299 A US 4197299A US 91733578 A US91733578 A US 91733578A US 4197299 A US4197299 A US 4197299A
- Authority
- US
- United States
- Prior art keywords
- ergoline
- methylthio
- beta
- compound according
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Definitions
- R II alkyl (C 1 -C 6 ), phenyl
- x Y CH 2 --CH ⁇ , CH ⁇ C ⁇ .
- aprotic solvents such as methylene chloride, chloroform, dichloroethane, tetrahydrofuran, ethylene glycol dimethylether, etc.
- reaction products can be separated and purified with usual methods such as for example crystallization, column chromatographic separation on SiO 2 , Al 2 O 3 , etc. Separation, purification and yield are greatly simplified and improved when the reaction products are treated with Raney Ni in alcoholic solvents such as methanol, ethanol, in a temperature range from 25° C. to 150° C. to eliminate all the labile secondary products of polysubstitution.
- alcoholic solvents such as methanol, ethanol
- the compounds of general formula I are generally solid, crystalline and provide pharmaceutically acceptable salts with inorganic acids such as hydrochloric, hydrobromic, sulphuric, phosphoric acid, or organic acids, such as maleic, tartaric, citric, methansulphonic, etc.
- inorganic acids such as hydrochloric, hydrobromic, sulphuric, phosphoric acid, or organic acids, such as maleic, tartaric, citric, methansulphonic, etc.
- the new compounds can be used as drugs as such or in the form of suitable salts with pharmaceutically acceptable acids, in doses of 0.1-10 mg.
- the pharmaceutical dosage form can be tablets, sugar-coated tablets, drops, vials, suppositories.
- the solid forms for oral use can be formulated by mixing the active ingredient with various vehicles and diluents, such as lactose, mannitol, starch, cellulose and derivatives thereof, and lubricants such as magnesium or calcium stearate.
- various vehicles and diluents such as lactose, mannitol, starch, cellulose and derivatives thereof, and lubricants such as magnesium or calcium stearate.
- the mixtures so obtained as treated to provide tablets or cores and these latter can be subsequently coated with sugar containing gum arabic, talc and a suitable lake or dye.
- the said pharmaceutical product can be formulated as hard or soft gelatin capsules.
- the active ingredient is preferably dissolved or suspended in a suitable liquid such as polyoxyethyleneglycol in the presence of a stabilizer such as sodium metabisulphite or ascorbic acid.
- a suitable liquid such as polyoxyethyleneglycol
- a stabilizer such as sodium metabisulphite or ascorbic acid.
- the active ingredient can be formulated for example in gelatin capsules for rectal use or with a vehicle for suppositories, for instance natural triglycerides such as cocoa butter.
- the solution for parenteral use or the drops for oral use can be prepared by dissolving the active ingredient as such or in the form of a salt in a suitable dissolving and stabilizing agent comprising for example only sterile water or water containing 5-20% of ethanol, glycerol, propyleneglycol.
- a suitable dissolving and stabilizing agent comprising for example only sterile water or water containing 5-20% of ethanol, glycerol, propyleneglycol.
- the compounds from 7 to 17 are prepared similarly.
- D-6-methyl-z-phenylthio-8beta perhydroazepinil carbonyloxymethyl)-ergoline (compound No. 20) is similarly prepared.
- the compounds claimed in the present invention show interesting pharmacological properties, evidenced by means of classical tests on laboratory animals at extremely low doses.
- the new compounds show alpha-blocking and vasodilator, anti-hypertensive, anti-serotonic both peripheral and central- and anti-asthmatic, anti-depressive and, in two cases, analgesic properties.
- compounds 11 and 9 have a broad spectrum of pharmacologycal properties, shown in the following table, compared to known substances used as comparison.
- the two new compounds 9 and 11 possess high adrenolytic and anti-serotininic activity and for such compounds a pharmaceutical use as psychopharmacologic drugs and vasedilators is foreseen.
- compound No. 10 shows itself to be active both as adrenolytic (EC 50 3.7 ng/ml and ED 50 20 ⁇ g/kg) and as spasmolytic (EC 50 2 ⁇ g/ml) and as antiasthmatic.
- This Table shows how some of the compounds listed are exceptionally active, up to 1000-2500 times the standard, and, in the absence of other important pharmacological activities except for a potent analgesic activity of compounds Nos. 12 and 14, the ED 100 which is 2.5 mg/kg/sc and 5 mg/kg/sc respectively, versus the ED 100 of D-propoxyphene, which is 10 mg/kg/sc, a pharmaceutical use is foreseen for said compounds, as anti-depressive drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH8255/77 | 1977-07-05 | ||
CH825577 | 1977-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
US4197299A true US4197299A (en) | 1980-04-08 |
Family
ID=4337542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/917,335 Expired - Lifetime US4197299A (en) | 1977-07-05 | 1978-06-20 | Anti-hypertensive derivatives of ergoline-2-thioethers and their sulphoxides |
Country Status (7)
Country | Link |
---|---|
US (1) | US4197299A (ja) |
JP (1) | JPS5414999A (ja) |
BE (1) | BE868768A (ja) |
DE (1) | DE2829471A1 (ja) |
FR (1) | FR2396758A1 (ja) |
GB (1) | GB2000772B (ja) |
IT (1) | IT1192260B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4382940A (en) * | 1979-12-06 | 1983-05-10 | Farmitalia Carlo Erba S.P.A. | Ercoline derivatives and therapeutic compositions having CNS affecting activity |
DE3413657A1 (de) * | 1984-04-09 | 1985-10-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue ergoline |
EP0207695A2 (en) * | 1985-06-24 | 1987-01-07 | Eli Lilly And Company | 4-dialkylaminotetrahydrobenz[c,d]indoles |
US4801712A (en) * | 1985-06-24 | 1989-01-31 | Eli Lilly And Company | 2-Alkyl(or phenyl)thio-6-n-alkylergolines are dopamine D-1 antagonists without D-2 agonist activity |
US5079364A (en) * | 1986-06-25 | 1992-01-07 | Farmitalia Carlo Erba | T-alkyl ergoline derivatives |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1193467B (it) * | 1978-01-26 | 1988-07-08 | Simes | Carbammati di omolisergoli (8 beta-idrossietilergoline) |
DE102007014947B4 (de) * | 2007-03-23 | 2010-05-27 | Axxonis Pharma Ag | Stabilisierte wässrige Lösungen von Ergolinverbindungen |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3324133A (en) * | 1964-04-14 | 1967-06-06 | Farmaceutici Italia | 2-nitrogen 6-methyl and 1, 6-dimethylergoline derivatives |
US3752814A (en) * | 1968-05-31 | 1973-08-14 | Sandoz Ltd | 2-bromo-alpha-ergocryptine |
US3901894A (en) * | 1974-06-06 | 1975-08-26 | Lilly Co Eli | 8-thiomethylergolines |
US3920664A (en) * | 1972-07-21 | 1975-11-18 | Lilly Co Eli | D-2-halo-6-alkyl-8-substituted ergolines and related compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1429210A (fr) * | 1964-04-14 | 1966-02-18 | Farmaceutici Italia | Nouveaux dérivés de méthyl.6 et diméthyl.1.6 ergoline, substitués en position 2, et leur procédé de préparation |
NL7416120A (nl) * | 1973-12-21 | 1975-06-24 | Farmaceutici Italia | Werkwijze voor het bereiden van pyrimidinoami- nomethylergolinederivaten. |
CH619709A5 (en) * | 1975-03-14 | 1980-10-15 | Siphar Sa | Process for the preparation of carbamates of 2-halogenoergolines and 2-halogenoergolenes |
HU172649B (hu) * | 1975-04-24 | 1978-11-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh biologicheski aktivnykh lizergamidov |
-
1978
- 1978-05-26 IT IT23911/78A patent/IT1192260B/it active
- 1978-06-20 US US05/917,335 patent/US4197299A/en not_active Expired - Lifetime
- 1978-06-30 JP JP7879378A patent/JPS5414999A/ja active Granted
- 1978-07-05 GB GB7828932A patent/GB2000772B/en not_active Expired
- 1978-07-05 BE BE189095A patent/BE868768A/xx unknown
- 1978-07-05 DE DE19782829471 patent/DE2829471A1/de active Granted
- 1978-07-05 FR FR7820054A patent/FR2396758A1/fr active Granted
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3324133A (en) * | 1964-04-14 | 1967-06-06 | Farmaceutici Italia | 2-nitrogen 6-methyl and 1, 6-dimethylergoline derivatives |
US3752814A (en) * | 1968-05-31 | 1973-08-14 | Sandoz Ltd | 2-bromo-alpha-ergocryptine |
US3920664A (en) * | 1972-07-21 | 1975-11-18 | Lilly Co Eli | D-2-halo-6-alkyl-8-substituted ergolines and related compounds |
US3901894A (en) * | 1974-06-06 | 1975-08-26 | Lilly Co Eli | 8-thiomethylergolines |
Non-Patent Citations (4)
Title |
---|
Dryhurst, G., Periodate Oxidation of Diol and Other Functional Groups, , Pergamon Press, Oxford, 1966, pp. 61-64. * |
Fusco-Bianchetti, Chimica Organica II, p. 584. * |
Kharasch, N., Organic Sulfur Compounds, vol. 1, Pergamon Press, New York, 1961, pp. 382-383. * |
Kirk-Othmer, Encyclopedia of Chemical Technology, vol. 7, Interscience, New York, 1951, p. 840. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4382940A (en) * | 1979-12-06 | 1983-05-10 | Farmitalia Carlo Erba S.P.A. | Ercoline derivatives and therapeutic compositions having CNS affecting activity |
DE3413657A1 (de) * | 1984-04-09 | 1985-10-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue ergoline |
EP0207695A2 (en) * | 1985-06-24 | 1987-01-07 | Eli Lilly And Company | 4-dialkylaminotetrahydrobenz[c,d]indoles |
US4683313A (en) * | 1985-06-24 | 1987-07-28 | Eli Lilly And Company | 2-alkyl(or phenyl)thio-6-N alkyl ergolines and 4-dialkylaminotetrahydrobenz[c,d]indoles |
EP0207695A3 (en) * | 1985-06-24 | 1988-01-27 | Eli Lilly And Company | 4-dialkylaminotetrahydrobenz[c,d]indoles |
US4801712A (en) * | 1985-06-24 | 1989-01-31 | Eli Lilly And Company | 2-Alkyl(or phenyl)thio-6-n-alkylergolines are dopamine D-1 antagonists without D-2 agonist activity |
US5079364A (en) * | 1986-06-25 | 1992-01-07 | Farmitalia Carlo Erba | T-alkyl ergoline derivatives |
Also Published As
Publication number | Publication date |
---|---|
IT1192260B (it) | 1988-03-31 |
DE2829471A1 (de) | 1979-02-15 |
GB2000772A (en) | 1979-01-17 |
GB2000772B (en) | 1982-02-24 |
DE2829471C2 (ja) | 1988-09-22 |
FR2396758B1 (ja) | 1981-06-26 |
JPS6225149B2 (ja) | 1987-06-01 |
FR2396758A1 (fr) | 1979-02-02 |
JPS5414999A (en) | 1979-02-03 |
IT7823911A0 (it) | 1978-05-26 |
BE868768A (fr) | 1978-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5270316A (en) | Condensed purine derivatives | |
EP0251315B1 (en) | Naphthalene derivatives, process for their preparation and pharmaceutical compositions containing the same | |
UA46697C2 (uk) | Похідні ксантину і їх фармакологічно переносимі солі | |
EP0315698A1 (en) | Thieno(triazolo)diazepine compounds and medicinal application of the same | |
LU81396A1 (fr) | Derives de phenylpiperazine | |
JPH01199971A (ja) | 芳香族化合物を有効成分とする抗ムスカリン剤 | |
EP0051829A1 (en) | N-substituted omega-(2-oxo-4-imidazolin-1-yl) alcanoic acids, salts and esters thereof, process for producing the same and these active agents containing pharmaceutical compounds | |
US5589472A (en) | Diindolo compounds and pharmaceutical compositions containing them | |
US4216216A (en) | Aromatic piperazinyl substituted dihydrouracils | |
US4197299A (en) | Anti-hypertensive derivatives of ergoline-2-thioethers and their sulphoxides | |
Ayer et al. | The structure of lycodine | |
EP0251937B1 (fr) | Nouveaux dérivés tricycliques agonistes des récepteurs cholinergiques et médicaments en contenant | |
EP0115979B1 (fr) | Nouveaux dérivés du 1H,3H-pyrrolo (1,2-c) thiazole leur préparation et les médicaments qui les contiennent | |
US4678785A (en) | Thiadiazine compounds | |
US4064244A (en) | Organic compounds | |
DK170733B1 (da) | Tetracykliske biocide alkylalkanolaminer, mellemprodukter til fremstilling deraf samt farmaceutiske præparater med indhold deraf | |
KR880001284B1 (ko) | 아지노 리파마이신 화합물의 제조방법 | |
US4496568A (en) | Antiinflammatory thieno [2,3-c]pyridine derivatives | |
US4861793A (en) | D-nor-7-ergoline derivatives having anti-Parkinson and antipsychosis activity and pharmaceutical compositions containing them | |
US4229450A (en) | Carbamates of homolysergols (8β-hydrohyethylergolines) and compositions thereof | |
DK170099B1 (da) | t-Butyl-ergolin-derivativer, fremgangsmåde til fremstilling deraf, samt farmaceutiske præparater indeholdende disse | |
US4576954A (en) | Anti-rheumatic 5-(substituted amino)-1,2-dithiol-3-one compounds and their use | |
NL8302776A (nl) | Moederkoornalkaloiden en werkwijzen voor hun bereiding en toepassing. | |
NL8004000A (nl) | Werkwijze voor de bereiding van een geneesmiddel op basis van ergolinederivaten en de bereiding van de actieve stof. | |
EP1129097B1 (en) | Novel type condensed pyridazinone compounds |